Key Inclusion Criteria:~1. Male or female age 50 to 80 years.~2. A clinical diagnosis of Alzheimer's disease
(AD) at either the mild cognitive impairment or mild AD dementia stage per National Institute on Aging and the
Alzheimer's Association, consistent with Stage 3 and Stage 4 in the Food and Drug Administration (FDA) draft
guidance for early AD.~3. Mini-Mental State Examination score of 20 to 28 (inclusive).~4. A plasma pTau217
result consistent with the presence of amyloid pathology.~5. Must have a care partner who, in the
investigator's judgment, has frequent and sufficient contact with the participant as to be able to provide
accurate information about the participant's cognitive and functional abilities. The care partner must be
literate and provide informed consent.~Key
